Knight Therapeutics (GUD) Announces Quarterly Earnings Results, Meets Estimates

Knight Therapeutics (TSE:GUD) issued its quarterly earnings data on Thursday. The company reported C$0.03 earnings per share (EPS) for the quarter, hitting the consensus estimate of C$0.03, reports. The firm had revenue of C$3.22 million for the quarter, compared to analyst estimates of C$2.26 million.

Shares of GUD stock opened at C$8.30 on Friday. Knight Therapeutics has a 1 year low of C$7.38 and a 1 year high of C$8.81.

Several equities analysts recently issued reports on GUD shares. TD Securities lifted their price objective on Knight Therapeutics from C$9.50 to C$10.00 in a report on Friday, August 10th. Bloom Burton reaffirmed an “accumulate” rating on shares of Knight Therapeutics in a report on Friday. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of C$10.15.

COPYRIGHT VIOLATION NOTICE: This story was first posted by WKRB News and is the property of of WKRB News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at

About Knight Therapeutics

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Read More: What is the Book Value of a Share?

Earnings History for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply